Probiotic supplement shows promise for gout prevention in small study
NCT ID NCT06969469
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed study tested whether a probiotic supplement called LUA Probiotics can lower uric acid levels in the blood. Twenty adults with high uric acid or gout who were not taking uric acid-lowering drugs took the supplement daily for 28 days. Researchers measured uric acid and other health markers at the start, after 2 weeks, and after 6 weeks to see if the probiotics made a difference.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- LUA probiotics (Lactobacillus reuteri, beta-carotene, silicon dioxide, magnesium stearate)
- What this could lead to
- If it works, this could point toward a dietary supplement to help lower uric acid and reduce gout flare-ups, possibly decreasing the need for medication.
- What could go wrong
- This is a very small, early-stage study with only 20 participants. Results may not apply to everyone, and the supplement is not yet proven effective or commercially available.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GOUT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Taiwan University Hospital
Taipei, 100229, Taiwan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new injection tame Gout's uric acid?
- Can an ancient herbal formula tame gout?
- New drug combo aims to tame stubborn gout flares
- Timing matters: study tests if starting gout drug during a flare is safe
- Ultrasound may solve arthritis diagnosis puzzle
- New gout drug dotinurad shows promise in early trial